TW201442732A - Reverse vesicle composition and method for producing same - Google Patents

Abstract

The present invention addresses the problem of providing a stable reverse vesicle composition using lecithin. The means for solving this problem is a reverse vesicle composition comprising a reverse vesicle including lecithin and an oil solution that has a molecular weight greater than 114 g/mol and is liquid at 25 DEG C.

Description

Anti-cyst composition and manufacturing method thereof

The present invention relates to a reverse vesicle cell, a vesicle composition, and a skin external preparation using the same, and methods for producing the same.

In addition to the pharmaceutical and food fields, it is expected to be used in the field of cosmetics, and various techniques have been applied to the field of cosmetics in the field of microcapsules, which are suitable for use in vivo and in vitro. Various studies.

In the technique of microencapsulation in the field of cosmetics, a cystic cell system in which a phospholipid such as lecithin is used as a dual film component has been known.

Lecithin is a natural lipid which has been widely used as an emulsifier or stabilizer in the field of cosmetics or food.

Historically, the cyst cells using lecithin mainly align the hydrophilic groups of the phospholipids to the outside, and disperse the cysts in the water dispersed in the aqueous phase.

On the other hand, an anthrone surfactant is introduced into a water-repellent anthrone to introduce a hydrophilic organic group, and is also used for various purposes due to the ease of molecular design.

In particular, in the field of cosmetics, a low HLB ketone ketone surfactant has been used as an emulsifier at the time of making a W/O emulsion. High HLB ketone ketone surfactant can impart hair and smoothness to the hair. For the antistatic effect, it has been used in hair care products such as O/W emulsions.

The following is known for the anti-cysts in which the hydrophobic group of the amphiphilic substance is aligned to the outside.

Patent Document 1 describes a reverse cyst using a sucrose fatty acid ester. Further, it has been described that the above-mentioned anti-cysts are used as an emulsifier, and an oil-in-oil emulsion is formed by a three-phase emulsification method.

Patent Document 2 describes the use of a reverse cystic composition of a sphingosine type.

Further, Non-Patent Document 1 describes the formation of a lecithin-containing anti-sac cell, and has been reported in cyclohexane, and specific lecithin forms a reverse vesicle.

On the other hand, Non-Patent Document 2 discloses that a lecithin having a different carbon chain as described above does not form a coexisting phase of a layered layer in the same oil agent as the oil necessary for forming the anti-cell.

Further, Non-Patent Document 3 discloses a reverse cyst composition using tetraethylene glycol dodecyl ether.

Non-patent document 4 describes a reverse cytoskeleton composition using a diglycerin fatty acid ester.

Non-patent document 5 has described a reverse cytoskeletal composition using polyoxyethylene oleyl ether (C18: 1 EO 50.8).

The above-mentioned anti-cytoplasmic cell is produced by mixing a lamellar phase of an anti-sac cell component with an oil agent by mixing with a physical stirring force by hand stirring or ultrasonic irradiation (refer to the above patent). Literature, non-patent literature).

In the conventional method of forming the anti-cytoplasm, the dispersion of the oil in the lamellar phase can be carried out by the weak stirring force due to the higher softness of the lamellar phase. In the method of high flexibility, it has been reported that the dimolecular film is important for the swell by the aqueous component and the oil component (Non-Patent Document 6).

[Previous Technical Literature] [Patent Literature]

[Patent Document 1] Japanese Patent Laid-Open Publication No. 2010-104946

[Patent Document 2] Japanese Patent Laid-Open Publication No. 2009-62365

[Non-patent literature]

[Non-Patent Document 1] S. Tung et al., Journal of the American Chemical Society, 2008, Vol. 130, No. 27, pp. 8813-8817

[Non-Patent Document 2] Langmuir, 2004, vol. 20, pp. 619-631

[Non-Patent Document 3] Langmuir, 1991, 7, 1915-1919

[Non-Patent Document 4] Langmuir, 2006, 22, 1449-1454

[Non-Patent Document 5] Langmuir, 1999, 15, 3118-3122

[Non-Patent Document 6] Langmuir, 1994, vol. 10, pp. 4006-4011

Historically, water-dispersing cystic cells are present in the interior and exterior of the capsule (the bulk) due to the aqueous phase, and the exchange of water-soluble components is likely to occur. Therefore, there is a problem in that the water-dispersible capsular cell composition has an insoluble stable water-soluble active ingredient.

On the other hand, as shown in Non-Patent Document 1, in the case where lecithin is combined with C4-lecithin in cyclohexane, although a reverse cytoskeletal composition can be formed, as shown in Non-Patent Document 2, other Lecithin Shape, the formation of anti-cytoplasmic cells is difficult.

Further, as shown in Non-Patent Document 1, in order to form a reverse vesicle stably in cyclohexane, it is necessary to add a salt such as NaCl.

The present invention has been made to solve the above problems, and to provide a composition of a reverse cytoskeleton using lecithin.

However, in the formation of the anti-cyst, it is necessary for the surfactant to form an equilibrium state of the bimolecular film.

The surfactants of the anti-cytoplasmic cells described in Patent Documents 1 and 2 and Non-Patent Documents 3 and 4 have a small hydrophilic group. When the hydrophilic group is changed greatly, the curvature of the two-molecular film becomes normal and does not form. Two molecular film.

When the two-molecular film component is easily mixed with the oil, the two-molecular film is liable to cause a structural change, and there is a problem that the selection of the entire system of the composition is difficult.

On the other hand, as described in Non-Patent Document 5, in order to form a reverse vesicle using a surfactant having a long hydrophilic group, it is necessary to add an oil solvent having a small molecular weight in order to make the curvature close to negative. However, an oil agent having an extremely small molecular weight is difficult to apply to an external preparation for skin due to a safety problem.

For the above reasons, when the skin external preparation containing the anti-sac cells is reviewed, the limitation of the surfactant which can be selected is large.

The present invention has been made to solve the above problems and to provide a novel anti-cyst composition. In particular, in the case of providing a surfactant having a large hydrophilic group, a state in which a bimolecular film is formed in a balanced state can be easily obtained, and a technique of stably producing a reverse cell is a problem.

On the other hand, the manufacturer of the anti-cell composition of the past In the case of using a large molecular weight oil agent, since the oil layer is not incorporated between the layers of the two-molecular film, the layered phase becomes rigid, and it is difficult to obtain a fine anti-cytoplasmic cell line. In particular, when a relatively large molecular weight oil agent which can be safely used for cosmetics or the like is used, it is necessary to give a large stirring force in order to obtain an anti-capsular cell, and it is also a problem from the viewpoint of manufacturing efficiency.

The present invention has been made to solve the above problems, and a novel production method for providing an anti-cyst composition is a subject. In particular, in the case of using an oil agent having a large molecular weight, a production method which is easy to form a composition of a cytosolic cell is provided as a problem compared with the conventional method.

<Anti-cyst composition containing lecithin>

The first invention for solving the above problems is an anti-cyst composition comprising a anti-sac cell containing lecithin and an oil agent having a molecular weight of more than 114 g/mol and being liquid at 25 °C.

In the anti-cyst composition of the present invention, the anti-cyst line of lecithin can be stably formed in an oil agent.

Further, the formation of the anti-cytoplasmic stability in the present invention means that the composition containing the anti-cysts does not separate the oil from the lamellar phase, and the anti-cyst is retained in the composition.

In a preferred embodiment of the present invention, the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil.

When such an oil agent is used, it becomes a highly safe anti-cyst composition suitable for cosmetics.

In a preferred aspect of the invention, the anti-cyst composition contains 40% by mass or more of the oil agent.

The anti-cyst composition containing 40% by mass of the aforementioned oil agent is highly formed by the anti-cyst.

In a preferred embodiment of the invention, the anti-cyst system contains water.

When the anti-sacs contain water, the formation of the anti-cysts is enhanced, and it becomes a higher stability anti-cyst composition. Further, for example, the water-soluble component which is an active ingredient of the cosmetic can be held in the anti-cyst. Further, the intracellular cells can also be used as a reaction site.

In a preferred embodiment of the present invention, the water content in the anti-cyst composition is 1 part by mass or less based on the content of the bimolecular film constituent component containing lecithin.

By making such a form, the anti-sacs of lecithin can be maintained more stably.

In a preferred embodiment of the present invention, the anti-capsular cell contains a water-soluble active ingredient.

The anti-cyst composition containing such an anti-cyst composition, for example, a living tissue such as a skin, is possible as a function of a composition exhibiting various activities.

In a preferred embodiment of the invention, the anti-cyst composition of the invention is non-emulsifying.

The anti-cytoplasmic composition of this form has high stability.

Further, the present invention is a skin external preparation containing the above-described anti-cyst composition of the present invention.

The external preparation for skin containing such an anti-cyst composition can maintain the water-soluble active ingredient in the anti-cytoplasm, thereby stably maintaining the effective The ingredients are in the formulation.

Further, the present invention is a method for producing an anti-cyst composition comprising mixing lecithin and an oil component having a molecular weight of more than 114 g/mol and being liquid at 25 ° C to prepare a mixture, and then oscillating Or stir the mixture.

According to the production method of the present invention, a stable composition containing a lecithin-containing anti-sacs cell can be efficiently produced.

Further, the present invention is a method for producing an anti-cyst, which comprises recovering a reverse vesicle from the above-described anti-cyst composition.

Further, the present invention is a skin external preparation containing the above-mentioned recovered anti-cyst.

<Anti-cyst composition of an anthrone-containing surfactant>

Further, the present invention which solves the problems relating to the size of the hydrophilic group and the molecular weight of the oil agent is a reverse cytoskeleton composition containing a thioglycolic surfactant-containing surfactant and water, and a liquid at 25 ° C. Oil agent.

The anti-cyst composition of the present invention is an anti-sac cell containing an anthrone surfactant and water which can be stably formed in an oil.

Further, the formation of the anti-cytoplasmic stability in the present invention means that the oil containing the anti-sacs is not separated from the lamellar phase, and the anti-sac is retained in the composition.

In a preferred embodiment of the present invention, the fluorenone surfactant is selected from the group consisting of polyoxyethylene modified fluorenone, polyoxypropylene modified fluorenone, and polyoxyethylene. Polyoxypropylene modified fluorenone, and polyglycerol modified fluorenone.

When such an oxime ketone surfactant is used, it becomes a reverse vesicle composition which can be used for an external preparation for skin.

In a preferred embodiment of the invention, the anthrone surfactant has an HLB of from 3 to 13.

When such an anthrone surfactant is used, the formation of the anti-sac cell of the anthrone surfactant increases.

In a preferred embodiment of the present invention, the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil.

When such an oil agent is used, it becomes a highly safe anti-cytoplasm composition for cosmetics.

In a preferred embodiment of the present invention, the anti-cyst composition contains 40% by mass or more of the oil agent.

The anti-cyst composition containing 40% by mass of the aforementioned oil agent has high formability of the anti-cyst.

In a preferred embodiment of the present invention, the water content of the water is one time or less of the mass of the constituent component of the two-molecular film containing the fluorenone surfactant.

By making such a morphology, the anti-cytoplasm of the fluorenone surfactant can be more stably maintained.

In a preferred embodiment of the present invention, the anti-capsular cell contains a water-soluble active ingredient.

The anti-cyst composition containing such a reverse granule, for example, for a living tissue such as the skin, is likely to be a function of a composition having various activities.

In a preferred embodiment of the invention, the anti-cyst composition is non-emulsifying.

The anti-cytoplasmic composition of this form has high stability.

Further, the present invention is a skin external preparation containing the above-described anti-cyst composition of the present invention.

The external preparation for skin containing such an anti-cyst composition retains the water-soluble active ingredient in the anti-capsular cell, whereby the active ingredient can be stably held in the preparation.

Further, the present invention is a method for producing an anti-cyst composition comprising mixing an anthrone surfactant, water, and a liquid component at 25 ° C to prepare a mixture, and then shaking or stirring the mixture mixture.

According to the production method of the present invention, the stabilizer composition containing the anti-cytoplasm containing the fluorenone surfactant can be efficiently produced.

Further, the present invention is a method for producing an anti-cyst, which comprises recovering a reverse vesicle from the above-described anti-cyst composition.

Further, the present invention is a skin external preparation comprising the above-mentioned recovered anti-cyst.

<Method for Producing Anti-cyst Composition 1>

The present invention for solving the problems related to the method for producing the above-described anti-capsular cell composition is a method for producing a reverse cyst composition, which comprises dissolving a dimolecular film component in a volatile solvent to obtain a first isotropic property. a step of (isotropy) a solution; a step of mixing the first isotropic solution with an oil agent to obtain a second isotropic solution; and a step of volatilizing the volatile solvent in the second isotropic solution; Volatilization of volatile solvents to reverse the composition of the above two molecules The volatilization step of cyst formation.

In this manner, the dimolecular film component is dissolved in a volatile solvent to form an isotropic solution, and then mixed with an oil agent, and then the volatile solvent is volatilized, and the layered phase is transferred from the isotropic solution to obtain a reverse Cyst composition.

According to the method for producing a cytosolic composition of the present invention, it is difficult to disperse a bimolecular film component in an oil agent even under physical agitation, for example, a system using a large molecular weight oil agent to produce a composition of the anti-cyst. The object is possible.

In particular, it is possible to easily manufacture a reverse cytoskeleton composition containing fine anti-sac cells.

In a preferred embodiment of the present invention, the volatile solvent is selected from the group consisting of alcohols, hydrocarbons, aromatics, ketones, ethers, esters, volatile fluorenone oils, and isoparaffins.

In the case of the volatile solvent, it is assumed that the produced anti-cyst composition is used for a skin external preparation such as cosmetics by using the above, and the safety can be improved.

In a preferred embodiment of the present invention, the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil.

When such an oil agent is used, it is assumed that the produced anti-cyst composition is used for a skin external preparation such as cosmetics, and the safety can be improved.

In the present invention, the dimeric film component is not particularly limited. For example, when the obtained anti-cyst composition is used as a component of cosmetics, lecithin and/or a nonionic surfactant are preferable.

In one aspect of the invention, the first isotropic solution may also contain The water of the two-molecular film component is one time or less of the mass.

In one aspect of the invention, the second isotropic solution is a two-phase solution in which particles of the first isotropic solution are dispersed in the oil agent.

Depending on the volatile solvent, the volatile solvent and the oil agent may form one phase and form two phases. However, in the latter case, by dispersing the particles of the first isotropic solution in the oil agent, the reverse can be produced. Cyst.

In a preferred embodiment of the invention, the volatilization of the volatile solvent is carried out under reduced pressure.

The present invention relates to a process for producing a reverse cytoskeleton comprising a lecithin-containing anti-sac cell and an oil agent having a molecular weight of more than 114 g/mol at 25 ° C.

Further, the present invention relates to a method for producing a reverse cytoskeleton comprising a sputum-containing surfactant and water-containing anti-sacs, and a liquid-based oil at 25 °C.

Further, the present invention relates to a method for producing a skin external preparation comprising mixing a reverse cytoskeleton composition produced by the above production method with other components.

<Method for Producing Anti-cyst Composition 2>

In addition to the above-described production method, the present invention provides a method for producing a reverse cytoskeleton composition, which comprises mixing a bimolecular film component and an oil agent, and heating each of them to obtain each a step of isotropic solution; a cooling step of cooling the isotropic solution; and forming a reverse cyst of the second molecular film component by the aforementioned cooling A step of.

In this manner, by mixing the two-molecular film component and the oil agent, the isotropic solution is prepared by heating, and when it is cooled, the phase transition from the isotropic solution to the layered phase is caused, and the anti-cyst composition can be obtained.

According to the method for producing a cytosolic composition of the present invention, even in a system in which it is difficult to disperse a bimolecular film component in an oil agent under physical agitation, for example, a system using a large molecular weight oil agent is used to produce a cytosolic composition. become possible.

In particular, it is possible to easily manufacture a reverse cytoskeleton composition containing fine anti-sac cells.

In a preferred embodiment of the present invention, the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil.

When such an oil agent is used, it is assumed that the produced anti-cyst composition is used for a skin external preparation such as cosmetics, and the safety thereof can be improved.

In the present invention, the dimeric film component is not particularly limited. For example, when the obtained anti-cyst composition is used as a component of a cosmetic, lecithin and/or a nonionic surfactant are preferable.

In one aspect of the invention, the isotropic solution may contain water having a mass of one or less times the mass of the two-molecular film component.

In a preferred embodiment of the present invention, the heating is performed to a temperature at which the dimeric film component and the oil agent form one phase of the isotropic solution.

Further, in this case, when the oil agent contains two or more oil agents, the heating system may be carried out until the second molecular film component and the oil agent are One less temperature at which one phase forms an isotropic solution.

In one aspect of the invention, the cooling is performed by diluting the isotropic solution with a cooling solvent at a lower temperature than the isotropic solution.

Moreover, in this aspect, it is preferable that the said cooling agent contains the said oil agent.

The present invention relates to a process for producing a reverse capsular cell containing lecithin-containing anti-sac cells and an oil agent having a molecular weight of more than 114 g/mol and a liquid state at 25 ° C.

Further, the present invention relates to a method for producing a reverse cytoskeleton comprising a sputum-containing surfactant and water-containing anti-cysts and a liquid-based oil at 25 °C.

Further, the present invention relates to a method for producing a skin external preparation comprising mixing a reverse cytoskeleton composition produced by the above production method with other components.

The anti-cyst composition of the present invention has high stability. Further, the anti-cyst composition of the present invention is possible to contain a water-soluble active ingredient in the anti-cyst of the anti-cyst composition, and it is also possible to use the pool in the anti-cytoplasm as a reaction site. . Further, the anti-cyst composition of the present invention is conceivable for use in a skin external preparation or food, and the like, and high safety can be achieved.

Further, the method for producing the anti-cyst composition of the present invention can efficiently produce the above-described anti-cyst composition.

Also, by using the anti-cyst composition of the present invention In this way, it is possible to easily manufacture an anti-cytoplasmic cell as compared with the conventional method of producing a reverse cyst.

In particular, in the case where an anti-cyst composition is produced using an oil agent having a large molecular weight, it is necessary to have no basis-based physical stirring force as compared with the case of using a conventional method, and it is possible to improve productivity in industrial production. Further, even in the case where a component or the like which is conventionally difficult to form a fine anti-sac is formed, it is possible to relatively easily produce a reverse vesicle composition containing a fine anti-sac.

1‧‧‧Dimolecular membrane composition

2‧‧‧ volatile solvent

3‧‧‧1st isotropic solution

4‧‧‧ oil agent

2.4‧‧‧One phase solution

5‧‧‧2nd isotropic solution

7‧‧‧Anti-cyst

8‧‧‧Anti-cyst composition

31‧‧‧ particles

L1‧‧‧ One-phase isotropic solution

Layer of L2‧‧‧ dimolecular membrane components

L1+L2‧‧‧ two-phase isotropic solution

Fig. 1 is a schematic view showing the steps of a method for producing the inverse cell composition 1 of the present invention. The phase states in each step are presented together.

Fig. 2 is a schematic view showing the steps of a method for producing the anti-vesicular composition 2 of the present invention. The phase states in each step are presented together.

Figure 3 is a graph showing the small angle X-ray scattering spectrum of lecithin/ascorbic acid 2-glucoside aqueous solution. The vertical axis represents the scattering intensity, and the horizontal axis represents the magnitude of the scattering vector.

Figure 4 is a graph showing the small angle X-ray scattering spectrum of an aqueous solution of lecithin/tranexamic acid. The vertical axis represents the scattering intensity, and the horizontal axis represents the magnitude of the scattering vector.

Fig. 5 is a view showing a small angle X-ray scattering spectrum of a lecithin/glycyrrhetinic acid 2 potassium aqueous solution. The vertical axis represents the scattering intensity, and the horizontal axis represents the magnitude of the scattering vector.

[Formation of the Invention]

<Anti-cyst composition containing lecithin>

Hereinafter, the form of the present invention for carrying out the anti-cyst composition containing lecithin will be described in detail.

The anti-cyst composition of the present invention contains a lecithin-containing anti-sac cell and an oil agent having a molecular weight of more than 114 g/mol and a liquid state at 25 ° C. Hereinafter, each component constituting the present composition will be described.

(1) Anti-cysts containing lecithin

The anti-cysts in the anti-cyst composition of the present invention comprise lecithin.

The lecithin which forms the anti-cyst of the present invention is extracted from a living body of plants, animals and microorganisms, and may be purified as desired or may be a synthetic. Preferably, lecithin derived from a plant of soybean, corn, groundnut, rapeseed, wheat, or the like, lecithin derived from an animal such as egg yolk, or the like can be used.

The lecithin of the present invention comprises phosphatidylcholine, phosphatidic acid, phospholipid glycerol, phospholipidinoinositol, phospholipid mercaptoethanolamine, phospholipid methyl alcoholamine, phospholipid thiol amide Acid, diphosphatidic acid, diphospholipid glycerol (cardiolipin), and the like.

Further, in the present invention, "lecithin" also includes hydrogenated lecithin, enzyme-decomposed lecithin, enzyme-decomposed hydrogenated lecithin, lysolecithin, and the like.

The carbon number of the fatty acid constituting the hydrophobic group portion of the lecithin is not particularly limited, and for example, a carbon number of 8 to 20, preferably 16 to 18 can be mainly used. Further, the fatty acid may be saturated or unsaturated. Further, the fatty acid may be a straight chain or a branched chain.

In particular, it is advantageous that the anti-cyst composition of the present invention can use a lecithin having an unsaturated fatty acid as a main component. Implementation as described later In the example, it is difficult to use a lecithin having a unsaturated fatty acid as a main component in a conventional anti-cell composition of cyclohexane as a solvent.

In the present invention, lecithin may be used in the form of a single type of the above compound, or may be used in the form of a mixture of the above plurality of phospholipids.

In the composition of lecithin, phospholipid choline is preferred, and for example, 20% by mass or more, preferably 50% by mass or more, of phospholipid choline is preferred.

Lecithin can be used by a commercial person. For example, a commercial item as follows can be used.

Lecinol S-10, Nikko Chemicals (hydrogenation: ○, PC (phospholipid choline) content: 25~30%)

Lecinol S-10E, Nikko Chemicals (hydrogenation: ○, PC content: 75~85%)

Lecinol S-10EX, Nikko Chemicals (hydrogenation: ○, PC content: >95%)

Basis LP-20, Nissin OilliO Company (hydrogenation: ×, PC content: 20~30%)

Basis LP-20H, Nissin OilliO Co., Ltd. (hydrogenation: ○, PC content: unconfirmed)

Basis LS-60HR, Nissin OilliO Company (hydrogenation: ○, PC content: 60~75%)

Basis LS-60, Nissin OilliO Company (hydrogenation: ×, PC content: unconfirmed)

Phospholipon 85G, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >85%))

Phospholipon 90G, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >94%))

Phospholipon 75IP, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >70%))

Phospholipon 90IP, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >90%))

Phospholipon 80H, H. Holstein GmbH & Co. KG ((hydrogenation: ○, PC content: >70%))

Phospholipon 90H, H. Holstein GmbH & Co. KG ((hydrogenation: ○, PC content: >90%))

Phospholipon 75 HIP, H. Holstein GmbH & Co. KG ((hydrogenation: ○, PC content: > 70%))

Phospholipon 90 HIP, H. Holstein GmbH & Co. KG ((hydrogenation: ○, PC content: >90%))

Lipoid E25, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >25%))

Lipoid E80, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >80%))

Lipoid E80S, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >64%))

Lipoid EPCS, H. Holstein GmbH & Co. KG ((hydrogenation: ×, PC content: >96%))

Epikron200, Cargill (hydrogenation: ×, PC content: >95%)

Epikron200SH, Cargill (hydrogenation: ○, PC content: unconfirmed)

Epikron100P, Cargill (hydrogenation: ×, PC content: unconfirmed)

Epikron100H, Cargill (hydrogenation: ○, PC content: unconfirmed)

PhosphoLipidPCSH70, Japan Seiki Co., Ltd. (hydrogenation: ○, PC content: about 70%)

Egg yolk lecithin PL-100E, Kewpie company (hydrogenation: ○, PC content: about 83%)

The lecithin-containing inverse cell line of the present invention is a small cell body of a bilayer membrane in which the fatty acid chain of the lecithin is oriented outward.

Further, the anti-sac cells in the present invention may contain an auxiliary surfactant (nonionic surfactant, ionic surfactant) other than lecithin as a bimolecular film constituent component.

In the present invention, among the constituent components of the bilayer membrane forming the anti-cytoplasm, lecithin is preferably 60% by mass or more, more preferably 80% by mass or more.

It is preferred that the anti-sac cell line of the present invention contains water. The water is held in the dimolecular membrane of the anti-cyst. Accordingly, the stability of the composition of the anti-sac cells is enhanced. Further, it is also possible to maintain a water-soluble active ingredient in the two-molecular film. The active ingredient is, for example, a component which is effective for improvement of skin tissue and improvement of health.

In the case where the anti-sacs are water-containing, the content of water is preferably 1 part by mass or less based on the content of the bimolecular film constituent component of lecithin. Further, the content of water is preferably a content of a constituent component of a dimolecular film containing lecithin. It is preferably 0.1 to 0.7 parts by mass. According to this, there is no excess water overflowing from the dimembrane membrane of the anti-cytoplasm, and it is possible to stably maintain the anti-cyst.

(2) an oil agent having a molecular weight greater than 114 g/mol at 25 ° C as a liquid

The oil agent which is used in the present invention having a molecular weight of more than 114 g/mol and which is liquid at 25 ° C constitutes the outer and inner phases of the above-mentioned anti-cell.

The oil agent is not particularly limited as long as it has a molecular weight of more than 114 g/mol and is liquid at 25 °C.

Herein, in the case of using an oil agent having a molecular weight of 114 g/mol or less, a coexistence phase of a layered phase and an oil agent which are necessary for formation of a reverse granule cannot be formed. However, when an oil agent having a molecular weight of more than 114 g/mol is used as an oil agent, the solubility of the lecithin to the oil agent can be lowered, and a coexistence phase of the layered phase and the oil agent can be formed.

The molecular weight of the oil agent is preferably 282 g/mol or more. However, in general, as the molecular weight becomes larger and the viscosity of the oil agent becomes higher, dispersion of the layered phase becomes difficult. Therefore, it is preferred that the oil agent has a molecular weight of at least a fluidity at room temperature.

Examples of the oil agent used in the present invention include an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, a fluorine oil, and the like.

2. Examples of the oxime oil include dimethyl polyoxy siloxane, methyl phenyl polyoxy siloxane, and dimethyl methoxy oxane. a cyclic oxime such as an organopolyoxane, an octamethylcyclotetraoxane, a decamethylcyclopentaoxane or a dodecamethylcyclohexaoxane such as a methylphenyloxane copolymer. Oxytomane, etc.

Among them, the above cyclic oxirane is preferably used.

As the hydrocarbon oil, a chain and a cyclic hydrocarbon such as an α-olefin oligomer, a light isoparaffin, a light-flowing isoparaffin, a squalane, a mobile paraffin, a flowing isoalkane, a hydrogenated isobutylene, and a different hydrocarbon may be mentioned. Octane, decane, isododecane, isohexadecane, polybutene, decyltetradecyl alcohol, and the like.

Examples of the ester oil include dioctyl succinate, diisobutyl adipate, dioctyl adipate, di(2-heptylundenyl) adipate, and diisopropyl sebacate. Ester, dioctyl sebacate, dibutyl octyl sebacate, diisostearyl malate, triethyl citrate, ethylene dioctylate, neopentyl glycol dioctanoate, propylene glycol dicaprate , dipentanoic acid neopentyl glycol, trimethylolpropane trioctyl acid, trimethylolpropane triisostearate, neopentyltetraol, ethyl acetate, butyl acetate, amyl acetate, neopentyl Acid octyl dodecyl ester, hexadecyl octanoate, isodecyl isononanoate, isotridecyl isononanoate, hexadecyl dimethyl octanoate, ethyl dodecanoate, hexyl decanoate, myristic acid Propyl ester, myristyl myristate, isohexyl myristate, octyl dodecanoate, isopropyl palmitate, octyl palmitate, hexadecyl palmitate, isohexade palmitate, Isostearyl palmitate, butyl stearate, hexyl decyl stearate, isopropyl isostearate, isohexadecyl isostearate, decyl oleate, oleyl oleate, oil Octyl octyl ester , linoleic acid ethyl ester, linolenic acid isopropyl ester, hexadecyl lactate, lactic acid myristyl ester, hydroxystearic acid cholesteryl ester, lauryl glutamic acid dioctyl dodecyl ester, laurel Isopropyl amide, ethylhexyl methoxycinnamate, tris(caprylic/capric) glyceride, dimer dilinolenic acid di(isostearate/phytosterol), tetraisoic Pentaerythritol ester of fatty acid, octyldodecyl stearyl hydroxy stearate, glyceryl tricaprylate, hexadecyl ethylhexanoate, and the like.

Examples of the natural animal and vegetable oils include avocado oil, almond oil, olive tree oil, wheat germ oil, safflower oil, jojoba oil, macadamin ternifolia oil, cottonseed oil, coconut oil, and the like.

As the fluorine oil, a perfluoro type oil can be cited.

(3) anti-cyst composition

The anti-cyst composition of the present invention is formed in the above oil agent to form the above-mentioned anti-cyst.

The upper limit of the content of the lecithin in the anti-cyst composition of the present invention is not particularly limited as long as it is a range in which the composition of the anti-cyst can be formed, and is usually 10% by mass, preferably 5% by mass, more preferably It is 2% by mass, and more preferably 1% by mass.

Further, the lower limit of the content of lecithin in the anti-cyst composition of the present invention is preferably 0.001% by mass, more preferably 0.01% by mass, still more preferably 0.1% by mass.

The lower limit of the content of the oil agent in the anti-cyst composition of the present invention is not particularly limited as long as it can form a composition of the anti-cyst composition, and is preferably 60% by mass, more preferably 80% by mass, and still more. Preferably, it is 90% by mass, more preferably 95% by mass.

By containing an oil agent in such a range, it becomes easy to form a coexisting phase of the lamellar phase and the oil agent, and the anti-sac cells are stably formed and held in the composition.

Further, the upper limit of the content of the oil agent in the anti-cyst composition of the present invention is not particularly limited, but is preferably 99.99% by mass, more preferably 99.90% by mass, still more preferably 99.00% by mass.

The anti-cyst composition of the present invention may contain water. In this case, as described above, it is preferred that water is retained in the anti-cyst.

Alternatively, a portion of the water in the composition can form an emulsion with the above oil agent. However, from the viewpoint of the stability of the anti-capsular cell, it is more preferable that the anti-cyst composition of the present invention is not an emulsifying type.

From this point of view, the quality of water in the anti-cyst composition is preferably equal to or less than the amount of lecithin. In this case, the separation of water from the lamellar phase can be suppressed, and most of the water can be retained in the anti-cyst.

The particle diameter of the anti-sac cell in the anti-cyst composition of the present invention is preferably 200 μm or less in the immediate state, and more preferably 20 μm, more preferably 2 μm or less. The smaller the particle diameter, the more difficult it is to settle in the dispersion. However, the particle diameter of this anti-cyst has no particular effect on the stability of the anti-cyst itself.

The particle diameter of the anti-sac cell can be determined by dynamic light scattering or laser diffraction.

The anti-cyst composition of the present invention may contain any components such as other preservatives, tackifiers, and fragrances, within a range that does not interfere with the formation of the anti-sac cells.

(4) Method for producing anti-cyst composition

The above anti-cytoplasmic composition can be carried out in the same manner as in the conventional production of cysts. That is, the lecithin and the oil agent are mixed with water as needed to prepare a mixture, which is then produced by shaking or stirring the mixture.

The oscillation system can be performed using a shaker or the like. Further, the stirring system can be carried out using an ultrasonic disperser or the like.

Further, the above-mentioned anti-cytoplasm composition is more preferably produced by a method for producing an anti-cyst composition of the present invention to be described later.

Confirmation of formation of anti-cysts can be confirmed, for example, by microscopic observation under polarized light.

Further, the anti-cyst composition can also be recovered from the anti-cyst composition prepared as described above. Also, the so-called recycling system herein includes the concept of concentration.

The method of the method is exemplified by the method of removing the supernatant after the anti-cyst composition is precipitated by the anti-cyst composition.

<Anti-cyst composition of an anthrone-containing surfactant>

Hereinafter, the form of the present invention relating to an oxime ketone surfactant will be described in detail.

The anti-cyst composition of the present invention contains an anti-cytoplasm containing an anthrone surfactant and water, and an oil agent which is liquid at 25 °C. Hereinafter, each component constituting the present composition will be described.

(1) Anti-cysts containing an anthrone surfactant and water

The anti-cytoplasmic cell of the anti-cytoplasmic composition of the present invention comprises an indolinone surfactant.

An anthrone surfactant is a surfactant having a polyorganosiloxane (an oxime chain) on a hydrophobic group. The hydrophilic group is preferably selected from polyether or polyglycerol. 2. In terms of polyether, polyoxyethylene, polyoxypropylene, or oxyethylene is preferred. Oxypropylene copolymer.

On polyoxyethylene or polyoxypropylene, oxyethylene. The average degree of polymerization of the oxypropylene copolymer and the polyglycerin is, for example, about 8 to 15.

The polyorganosiloxane can be either linear or branched. Further, a plurality of polyorganosiloxane chains can be crosslinked. Also, the indolone chain can be modified with an alkyl group.

The HLB system of the fluorenone surfactant is preferably from 3 to 13, more preferably from 6 to 10.

The fluorenone surfactant is preferred for the oil to be soluble or dispersible. Further, it is preferred to use a liquid at room temperature.

In the present invention, the fluorenone surfactant may be used in the form of a single type of the above compound, or may be used in the form of a mixture of plural kinds.

These ketone ketone surfactants are known as raw materials for cosmetics, and any of them can also be used.

The fluorenone surfactant can be used by a commercial one. For example, a commercial item as follows can be used.

. SH3772M (PEG-12 dimeticone (polyoxyethylene type), HLB: 6, Dow Corning Toray)

. SH3773M (PEG-12 Dimethyl Ether (Polyoxyethylene), HLB: 8, Dow Corning Toray)

. FZ2222 (polyfluorenone-13 (oxyethylene. oxypropylene type), HLB: 6, Dow Corning Toray)

. KF6013 (PEG-9 dimethyl hydrazine oil ((polyoxyethylene type)), HLB: 10, Shin-Etsu Silicone)

. KF6100 (polyglycerol-3 dioxane dimethyl hydrazine oil (polyglycerol), Shin-Etsu Silicone)

The anti-cytoplasmic cell of the present invention is a small cell body of a bilayer membrane in which the oxime chain of the above-described fluorenone surfactant is aligned outward.

Further, the anti-sac cell in the present invention may contain an auxiliary surfactant other than an anthrone surfactant (nonionic surfactant, ionic interface activity) The agent) is a constituent component of the dimolecular film.

In the present invention, the fluorenone surfactant is preferably 50% by mass or more, more preferably 80% by mass or more, and more preferably 80% by mass or more.

The anti-sac cell line in the present invention contains water. The water is held in the dimolecular membrane of the anti-cyst. Further, it may be an active ingredient that retains water solubility in the dimolecular film. The active ingredient is, for example, a component which is effective for improvement of skin tissue and improvement of health.

The content of water is preferably 1 part by mass or less based on the content of the two-molecular film constituent component of the fluorenone-containing surfactant. Further, the content of water is preferably from 0.05 to 0.7 parts by mass based on the content of the two-molecular film constituent component of the fluorenone-containing surfactant. According to this, the dimolecular membrane of the self-reverse cystic cell does not overflow with excess water, and it is possible to stably maintain the anti-cyst.

(2) Liquid oil at 25 ° C

The oil agent which is liquid at 25 ° C used in the present invention constitutes the outer and inner phases of the above-mentioned anti-cell. The oil agent is preferably at least a molecular weight at a flow rate at room temperature.

The oil agent used in the present invention can be the same as the oil agent described in <Anti-cyst composition of lecithin-containing>.

(3) anti-cyst composition

The anti-cyst composition of the present invention is formed in the above oil agent to form the above-mentioned anti-cyst.

The upper limit of the content of the fluorenone surfactant in the anti-cyst composition of the present invention is not particularly limited as long as it is a range in which the composition of the cytosolic cell can be formed, and is usually 10% by mass, preferably 5% by mass. %, more preferably 2 The mass % is also preferably 1% by mass.

Further, the lower limit of the content of the fluorenone surfactant in the anti-cyst composition of the present invention is preferably 0.01% by mass, more preferably 0.1% by mass.

The anti-cyst composition of the present invention contains water. In this case, as described above, it is preferred that water is retained in the anti-cyst.

Alternatively, a portion of the water in the composition can form an emulsion with the above oil agent. However, from the viewpoint of the stability of the anti-capsular cell, it is more preferable that the anti-cyst composition of the present invention is not an emulsifying type.

From this point of view, the quality of water in the anti-cyst composition is preferably equal to or less than the amount of the fluorenone surfactant. When this is done, the separation of water from the lamellar phase can be suppressed, and most of the water can be retained in the anti-cyst.

The lower limit of the content of the oil agent in the anti-cyst composition of the present invention is not particularly limited as long as it can form a range of the anti-cyst composition, but is preferably 60% by mass, more preferably 80% by mass. More preferably, it is 90% by mass, and more preferably 95% by mass.

Since the oil agent is contained in such a range, the coexistence phase of the layered phase and the oil agent is easily formed, and the anti-capsular cell is stably formed and retained in the composition.

Further, the upper limit of the content of the oil agent in the anti-cyst composition of the present invention is not particularly limited, but is preferably 99.99% by mass, more preferably 99.90% by mass, still more preferably 99.00% by mass.

The particle diameter of the anti-sac cell in the anti-cyst composition of the present invention is preferably 200 μm or less in the state immediately after the preparation, and more preferably 20 μm, more preferably 2 μm or less. The smaller the particle diameter, the more difficult it is to settle in the dispersion. However, the particle diameter of this anti-cyst is self-anti-cystic There is no particular impact on the stability of the body.

The particle diameter of the anti-sac cell can be determined by dynamic light scattering or laser diffraction.

The anti-cyst composition of the present invention may contain any components such as other preservatives, tackifiers, and fragrances, within a range that does not interfere with the formation of the anti-sac cells.

(4) Method for producing anti-cyst composition

The production of the anti-cytoplasmic composition containing the above-described fluorenone surfactant can be carried out in the same manner as in the conventional production of the vesicles, similarly to the anti-cyst composition containing lecithin. Further, it is more preferable that the above-mentioned anti-cyst composition is produced in accordance with the method for producing the anti-cyst composition of the present invention to be described later.

Confirmation of the formation of anti-cysts, for example, can be confirmed by microscopic observation.

Further, it is also possible to recover the anti-cysts from the anti-cyst composition prepared as described above. Also, the so-called recycling system herein includes the concept of concentration.

The method of the method is exemplified by the method of removing the supernatant after the anti-cyst composition is precipitated by the anti-cyst composition.

(5) Skin external preparation

The anti-cyst composition containing the lecithin or an oxime ketone surfactant of the present invention can be used as a raw material for a skin external preparation. Of course, the anti-cyst composition of the lecithin- or ketone-containing surfactant of the present invention can also be directly used as a skin external preparation.

A skin external preparation containing such an anti-cyst composition is intended to be water-soluble The active ingredient is retained in the anti-capsular cell, whereby the active ingredient can be stably maintained in the formulation. As such an aqueous active ingredient, preferred are tranexamic acid, glycyrrhizic acid or a salt thereof, ascorbic acid, ascorbyl phosphate, 3-O-ethyl ascorbic acid, ascorbyl glucoside or a salt thereof. Various kinds of vitamin B such as ursolic acid, arbutin, ursolic acid potassium phosphate, pyridoxine, riboflavin or the like , hyaluronic acid or its salt, fucoidan, trehalose or its salt, trehalose, amino acid and amino acid derivatives, aesculetin glycoside, plant extract Matter (including liquid or solid shape) and so on.

The external preparation for skin may be exemplified by medicine or cosmetics, but the anti-cyst composition of the present invention is particularly preferably used as a raw material for cosmetics.

For example, the anti-cyst composition of the present invention can be directly used as a skin external preparation in the form of a lotion or oil. Further, the anti-cyst composition of the present invention is mixed with other components, and if necessary, it may be emulsified or the like, and may be used as a skin external preparation in the form of a lotion or a cream. Further, by mixing the anti-cyst composition of the present invention with the raw material powder of the cosmetic, it is also possible to form a powder-type cosmetic.

<Method for Producing Anti-cyst Composition 1>

Hereinafter, the form of the present invention for carrying out the production method of the anti-cyst composition will be described in detail with reference to Fig. 1 .

(1) Step of obtaining the first isotropic solution

In the production method of the present invention, first, the dimolecular film component 1 is dissolved The first isotropic solution 3 was obtained on Volatile Solvent 2.

The two-molecular film component indicates a constituent component of a two-molecular film constituting the anti-sac.

The constituent component of the bimolecular film is not particularly limited as long as it is an amphiphilic substance, and any of an ionic surfactant and a nonionic surfactant may be used. Preferred are lecithins of two ionic surfactants. Further, a nonionic surfactant can be preferably used. For example, an anthrone surfactant, a polyoxyethylene alkyl ether, a sucrose fatty acid ester, a neuroamine alcohol, a fatty acid or the like can be preferably used.

The production method of the present invention is effective in the case where the bimolecular film is rigid and lecithin which is difficult to form a reverse vesicle by physical stirring is conventionally used. Further, when the anti-cyst composition produced by the production method of the present invention is used for cosmetics or the like, a nonionic surfactant such as lecithin or an anthrone surfactant is preferably used because of safety and the like.

In the case where the anti-cyst composition containing lecithin or an anthrone surfactant is produced by the production method of the present invention, the lecithin or an anthrone surfactant can be used without limitation [the lecithin-containing anti-cyst composition] or Various lecithin or fluorenone surfactants described in paragraphs of the "Anti-cyst composition of an anthrone-containing surfactant".

Further, in the case where lecithin is used as a main component, it may be combined with other auxiliary surfactant (nonionic surfactant, ionic surfactant).

In this case, among the bimolecular film components forming the anti-sac cells, lecithin is preferably 60% by mass or more, more preferably 80% by mass or more.

a volatile solvent that dissolves the above two molecular film components Examples thereof include alcohols such as methanol, ethanol, propanol, and isopropanol; hydrocarbons such as pentane, hexane, and cyclopentane; aromatics such as benzene; ketones such as acetone; and ethers. Volatile oxime oils such as esters, decamethylpentaoxane, fluorocarbons, isoalkanes, and the like.

Among them, ethanol, propanol, acetone, and the like are preferably used.

The content of the dimeric film component in the first isotropic solution may be a range in which the dimolecular film component is sufficiently dissolved. For example, the content of the dimolecular film component can be targeted as 10 to 90% by mass. When the amount is less than 10% by mass, the volatilization time of the volatile solvent may become longer. When the amount is more than 90% by mass, the solution becomes viscous and becomes difficult to dissolve.

Further, the first isotropic solution may also contain water.

The manufacturing method of the present invention is intended to form a reverse vesicle without relying on conventional physical agitation, and does not require the presence of water for the purpose of dispersing physical agitation. Of course, it is useful for a system with less water.

However, in the formation of the anti-cell which is volatilized by the aforementioned volatile solvent, the presence of water may assist in the formation of the bimolecular film.

From the viewpoint of the above, in the present invention, water having a mass of one or less times the molecular component of the two molecules can be contained. Further, in this case, the dimolecular film component is mixed with water and then mixed with a volatile solvent (Fig. 1(a)). Of course, it is possible to mix a bimolecular film component, water, and a volatile solvent.

In the present invention, the first isotropic solution 3 is prepared by dissolving the dimeric film component 1 in the volatile solvent 2. This preparation can be carried out by usual mixing and stirring.

Obtained by dissolving the dimeric film component 1 in the volatile solvent 2 described above The first isotropic solution 3 is a combination of a state in which the dimeric film component 1 is monodispersed in the volatile solvent 2 or a micelle in which the dimeric film component 1 is formed in the volatile solvent 2; State (Fig. 1(b)).

Such an isotropic solution has a high fluidity, and is then easily mixed with an oil agent.

(2) Step of obtaining a second isotropic solution

In the production method of the present invention, the first isotropic solution 3 obtained above and the oil agent 4 are mixed to obtain the second isotropic solution 5.

The oil agent used in the present invention can be the same as the oil agent described in <Anti-cyst composition of lecithin-containing>. Further, the oil agent is not particularly limited as long as it can be mixed with the first isotropic solution, but it can be preferably used as a liquid oil at 25 °C.

The mixing ratio of the first isotropic solution and the oil agent can be such that the content of the dimeric film component in the produced anti-cyst composition is in the range of 0.1 to 10% by mass.

By mixing the first isotropic solution 3 and the oil agent 4, an isotropic solution (second isotropic solution) 5 in which the dimeric film component 1 is dispersed in the oil agent 4 can be obtained.

Among them, the form of dispersion of the diolecular film component with respect to the oil agent varies depending on the solubility of the volatile solvent to the oil agent.

(1) When the volatile solvent 2 is soluble in the oil agent 4, the first isotropic solution 3 is compatible with the oil agent to form a solution of one phase. In other words, the dimeric film component 1 contained in the first isotropic solution 3 is in a state of being monodispersed in the solution 2.4 of one phase, or exists in a state of being formed by a convergent body such as an antipo cell (No. 1 Figure (c)).

(2) On the other hand, when the volatile solvent 2 is insoluble or poorly soluble in the oil agent 4, the first isotropic solution 3 is incompatible with the oil agent 4 to form a two-phase solution. That is, in the continuous phase of the oil agent 4, the particles 31 of the first isotropic solution 3 are in a dispersed state (Fig. 1 (d)). The particle 31 is a state in which the dimeric film component 1 is monodispersed in the volatile solvent 2 or an antimolecular cell which is a dimeric film component 1 in the volatile solvent 2, as shown in Fig. 1 (d2). The state of the formation of the body.

Further, this state is in the step of mixing, and can be easily formed by an operation of usual shaking or stirring.

Further, when a component which is hardly soluble in an oil agent and a component which is soluble in an oil agent are used in combination as a two-molecular film component, a component which is hardly soluble in an oil agent is dissolved in a volatile solvent, and is soluble in an oil agent. The ingredients are dissolved in an oil and may be mixed.

<3> Step of volatilizing a volatile solvent

In the production method of the present invention, the volatile solvent 2 is volatilized from the second isotropic solution 5 obtained by the above operation.

The volatilization of the volatile solvent can be carried out by vaporizing the volatile solvent under reduced pressure by a conventional method. Further, it can be carried out by heating the mixed solution to a temperature at which the volatile solvent is vaporized. It is preferred that the volatilization is carried out under reduced pressure. Further, in the case of heating, it is possible to maintain the temperature below the temperature of the lamellar phase (reverse vesicle), that is, below the temperature at which the phase is not transferred.

In the case where the second isotropic solution is formed into two phases, it is preferred that the first isotropic solution is sufficiently dispersed in the oil by shaking or stirring.

Moreover, from the viewpoint of forming a fine anti-cytoplasm, stirring is imparted in the volatilization It is also better.

As described above, by volatilizing the volatile solvent 2, the second isotropic solution is phase-transferred, and the anti-sac cell 7 in the oil agent 4 can be obtained as a dispersed anti-cyst composition 8 (Fig. 1(e) ). The state of the formed anti-cysts is not limited to a single layer or multiple layers. The confirmation of the formation of the anti-cysts can be confirmed, for example, by microscopic observation under polarized light.

The particle diameter of the anti-sac cell in the anti-cyst composition thus produced is, for example, 200 μm or less, more preferably 20 μm, and more preferably 2 μm or less. The smaller the particle diameter, the more difficult it is to settle in the dispersion. However, the particle diameter of this anti-cyst has no particular effect on the stability of the anti-cyst itself.

The particle diameter of the anti-sac cell can be determined by dynamic light scattering or laser diffraction.

The anti-cyst composition of the present invention may contain any components such as other preservatives, tackifiers, and fragrances, within a range that does not interfere with the formation of the anti-sac cells.

Further, it is also possible to recover the anti-cysts from the anti-cyst composition prepared as described above. Also, the so-called recycling system herein includes the concept of concentration.

In this method, a method in which the anti-cyst composition is precipitated and the supernatant is removed after the anti-capsular cell is sedimented can be cited.

<Method for Producing Anti-cyst Composition 2>

In addition to the above methods, the anti-cyst composition can also be produced by the following method.

Hereinafter, the composition of the anti-cysts will be described in detail with reference to FIG. 2 The invention of the method of producing the article.

(1) Step of obtaining an isotropic solution

In the production method of the present invention, first, a mixture of the two-molecular film component 1 and the oil agent 2 is heated and mixed to obtain an isotropic solution 3. In this embodiment, at this point, the layered material (Lα) of the dimeric film component 1 is dissolved in the oil agent 2 (L1) to form a one-phase isotropic solution 3 (L1).

The two-molecular film component exhibits a constituent component of a bimolecular film constituting the anti-sac.

The constituent component of the bimolecular film is not particularly limited as long as it is an amphiphilic substance, and any of an ionic surfactant and a nonionic surfactant can be used. Preferred are lecithins of two ionic surfactants. Further, a nonionic surfactant can be preferably used. For example, an anthrone surfactant, a polyoxyethylene alkyl ether, a sucrose fatty acid ester, a neuroamine alcohol, a fatty acid or the like can be preferably used.

The production method of the present invention is extremely effective in the case of using a lecithin in which the bimolecular film is rigid and which is difficult to form an anti-sac cell by conventional physical stirring. Further, when the anti-cyst composition produced by the production method of the present invention is used for cosmetics or the like, it is preferable to use a nonionic surfactant such as lecithin or an anthrone surfactant for safety or the like.

In the case where the anti-cyst composition containing lecithin or an anthrone surfactant is produced by the production method of the present invention, the lecithin or anthrone surfactant is not limited to <anti-cytosolic composition containing lecithin> or < Various lecithin or fluorenone surfactants described in the paragraphs of the anti-cytosolic composition containing an anthrone ketone surfactant are used.

In the present invention, the aforementioned dimolecular film component and the aforementioned oil agent The mixture obtained by mixing is heated. Further, the dimeric film component and the oil agent may be mixed while being heated.

As the oil agent, it can be preferably used as a liquid oil at 25 ° C. The oil agent used in the present invention can be the same as the oil agent described in <Anti-cyst composition containing lecithin>.

The oil agent may be used alone or in combination of two or more. Further, in the case of mixing two or more types, the oil agents dissolved in each other may be combined, or the oil agents which are not dissolved in each other may be combined.

The mixing ratio of the dimeric film component to the oil agent can be such that the content of the dimeric film component in the produced anti-cyst composition is in the range of 0.1 to 10% by mass.

The heating system is carried out to a layered material of the dimeric film component 1 (Fig. 2(a)) for phase transfer, and the mixture is preferably an isotropic solution. Whether or not it becomes an isotropic solution can be observed by passing through a polarizing plate.

Further, the isotropic solution obtained by heating may be one phase or two phases, but heating to one phase is more preferable (refer to Fig. 2(b), L1). Further, in the case where the oil agent contains two or more kinds of oil agents, it is preferred that the second molecular film component is subjected to a temperature of an isotropic solution which is one phase with at least one of the oil agents.

The one-phase or two-phase system of the isotropic solution can be distinguished by observing the presence or absence of separation by placing it at a certain temperature or by measuring the light transmittance of the solution.

The phase transition temperature of the above mixture varies depending on the combination of the dimolecular film component and the oil agent to be used. Therefore, in view of the combination of these, it is preferable to adjust the heating temperature in consideration of the phase transition temperature.

For example, when lecithin is used as the dimolecular film component and squalane is used as the oil agent, the phase transition from the lamellar phase to the two-phase isotropic solution can be seen at around 65 ° C, and it can be seen from the vicinity of 90 ° C. The isotropic solution is transferred to the phase of one phase of the isotropic solution. Accordingly, the heating temperature in this case may preferably be 65 ° C or higher, more preferably 90 ° C or higher.

The isotropic solution 3 obtained by heating the mixture of the two-molecular film component 1 and the oil agent 2 is in a state in which the anti-micromolecule of the dimeric film component 1 is formed in the oil agent 2 (Fig. 2(b)).

Further, in the present embodiment, the form is heated to a one-phase isotropic solution, but it may be heated to a two-phase isotropic solution (L1+L2) as shown in Fig. 2(c). form. The combination of lecithin and squalane is a state in which the highly viscous isotropic solution (L2) and the oil agent (L1) which are contained in the oil-containing agent 2 containing the di-membrane component 1 are phase-separated.

In the case of forming a two-phase isotropic solution, stirring before cooling and/or cooling is important to obtain a dispersed state.

Further, the mixture of the above dimolecular film component and the oil agent may further contain water.

Since the manufacturing method of the present invention does not rely on the conventional physical agitation to form an anti-cyst, it does not require the presence of water for the purpose of dispersing physical agitation, and it is of course useful in a system in which water is scarce.

However, in the formation of the anti-cell which is cooled by the latter, the presence of water can assist in the formation of the bimolecular film.

From the viewpoint of the above, in the present invention, water having a mass of one or less times the molecular component of the two molecules can be contained.

The smaller the water content, the lower the transfer temperature to the isotropic solution. Accordingly, considering the case of the manufacturing efficiency in the present invention, it is also advantageous to have a small water content.

(2) Step of cooling the isotropic solution

In the production method of the present invention, next, the isotropic solution 3 obtained through the above operation is cooled.

The cooling method is not particularly limited, and examples thereof include a method of placing an isotropic solution at a temperature lower than room temperature, a method of cooling by a refrigerant, and the like. Further, it can be cooled by mixing a diluted solvent of a lower temperature than the mixed isotropic solution. For example, in the case of a dilute solvent, the cooled oil may be mixed.

The cooling temperature is that the isotropic solution is phase-transferred, and the temperature at which the layered liquid crystal and the oil agent coexist is formed at a temperature or lower. As far as the target is concerned, it can be exemplified by cooling to room temperature.

Further, from the viewpoint of forming fine anti-pocket cells, it is also preferable to impart a stirring force during cooling.

Further, as the cooling rate is increased (quickly cold), it is possible to form fine anti-cells, and such a form is also preferable.

As described above, the anti-cell composition 5 in which the anti-sacs 4 is dispersed in the oil agent 2 can be obtained by cooling the isotropic solution 3 and transferring the phase.

The isotropic solution is in a heated state to form an isotropic solution containing an anti-microcell or the like (Fig. 2(b)). When the isotropic solution is cooled, according to the system, the process of phase separation of the highly viscous isotropic solution containing the reversed-like micelles (Fig. 2(c)) finally forms the anti-sacs 4 (2nd) Figure (d)).

Confirmation of the formation of the anti-cysts can be confirmed, for example, by microscopic observation under polarized light.

The particle diameter of the anti-sac cell in the anti-cyst composition thus produced is, for example, 200 μm or less, more preferably 20 μm, and more preferably 2 μm or less. The smaller the particle diameter, the more difficult it is to settle in the dispersion. However, the particle diameter of the anti-cyst has no particular effect on the stability of the anti-cyst itself.

The particle diameter of the anti-sac cell can be determined by dynamic light scattering or laser diffraction.

The anti-cyst composition of the present invention may contain any components such as other preservatives, tackifiers, and fragrances, within a range that does not interfere with the formation of the anti-sac cells.

Further, the anti-cyst composition can be recovered from the anti-cyst composition prepared as described above. Also, the so-called recycling system herein includes the concept of concentration.

The method of the method is exemplified by the method of removing the supernatant after the anti-cyst composition is precipitated by the anti-cyst composition.

The anti-cyst composition produced by the above-described production methods 1 and 2 of the anti-cyst composition of the present invention can be used as a raw material for a skin external preparation. Of course, the anti-cyst composition prepared by such a method can also be directly used as an external preparation for skin.

The external preparation for skin may, for example, be a medicine or a cosmetic, and particularly preferably a cosmetic.

For example, the above-mentioned anti-cyst composition can be used as a skin external preparation in the form of a lotion or oil by using or adding an optional component as it is. Further, the above-mentioned anti-cyst composition is mixed with other components and emulsified as necessary. Alternatively, a skin external preparation in the form of a lotion or a cream may be used. Further, by mixing the above-mentioned anti-cyst composition with the raw material powder of the cosmetic, it is also possible to form a powder type cosmetic.

[Examples]

<Anti-cyst composition containing lecithin>

(1) Test example 1

The components shown in Table 1 were mixed, and the layered phase was dispersed in an oil agent by a tubular ultrasonic disperser (product name: VCX130 (manufactured by Sonics & Materials)).

Thereafter, a polarizing microscope was used to confirm the formation of the anti-cyst. The formation of the anti-sac cells is described as ○, and the formation of the anti-sac cells is not confirmed as ×.

As shown in Table 1, the formation of the anti-cysts was confirmed using B, D~J of an oil agent having a molecular weight of more than 114 g/mol, in the case of using hydrogenated lecithin, and in the case of using lecithin.

On the other hand, when A and C using an oil agent having a molecular weight of 114 g/mol were observed, the use of hydrogenated lecithin A confirmed the formation of the anti-cyst, but the use of lecithin did not confirm the formation of the anti-sac. .

From this, it can be seen that when an oil agent having a molecular weight of more than 114 g/mol is used, the type of lecithin is not restricted, and the anti-sac cells can be formed.

(2) Test example 2

It was confirmed that a combination of lecithin and an oil agent different from Test Example 1 had anti-cyst formation. The lecithin and oil used were shown in Table 2. A mixture containing 0.8% by mass of lecithin, 0.2% by mass of water, and 99% by mass of an oil agent was prepared, and the layered phase was dispersed in the oil using a tubular ultrasonic disperser. Thereafter, the formation of the anti-sacs was confirmed using a polarizing microscope. The person who confirmed the formation of the anti-sac cell was described as ○, and the person whose anti-sac cell was not confirmed was described as ×. Further, the combination of the lecithin and the oil agent which were not tested was shown in Table 2 as a blank column.

The combination of all the lecithin and the oil agent tested as shown in Table 2 confirmed the formation of the anti-sac cells.

From the results of Test Examples 1 and 2, when an oil agent having a molecular weight of more than 114 g/mol was used, it was found that the type of lecithin was not restricted, and a reverse vesicle was formed.

(3) Test example 3

It is examined whether the crystalline water-soluble active ingredient hinders the formation of a lamellar phase necessary for the formation of anti-sac cells. In this test example, three types of crystalline water-soluble active ingredients of ascorbic acid 2-glucoside, tranexamic acid, and potassium potassium glycyrrhizinate were examined.

First, the solubility of the above three components in water was reviewed. The results are shown in Table 3.

As shown in Table 3, 40% aqueous solution of ascorbic acid 2-glucoside, 10% aqueous solution of tranexamic acid, and 10% aqueous solution of licorice salicylic acid were used as the highest concentration aqueous solution in which each component was dissolved, and used for review. Lecithin (Epikuron 200) was mixed with the respective aqueous solution at 8:2, and the mixture was observed for the presence of the lamellar phase using small angle X-ray scattering. In the case where the layered phase is formed, a scattering spectrum peculiar to the layered phase having a peak ratio of 1:2 can be observed. The measurement results of the small-angle X-ray scattering of each mixture are shown in Figures 3 to 5.

As shown in the third to fifth figures, a scattering spectrum peculiar to the layered phase having a peak ratio of 1:2 was obtained for all the mixtures. That is, the water-soluble active ingredient of either of them did not inhibit the formation of the lamellar phase, and was confirmed to be contained in the lamellar phase.

If the layered phase formed as in this test example is used for the shape of the anti-cyst In this way, an anti-cyst composition containing a water-soluble active ingredient can be obtained.

(3) Skin external preparation

Hereinafter, examples of the external preparation for skin (cosmetic) of the present invention will be described. The blending amount of each component is expressed by mass percentage.

Example 1. Hair oil

After premixing the components of the group (A), the components of the group (B) are mixed and dispersed by an ultrasonic disperser.

As a result, a hair follicle (anti-cytoplasmic solution) containing anti-sac cells was produced.

Example 2. Cream

(C-2) Squalane 98

The anti-cytosolic solution (C) was prepared by premixing (C-1, 2) by dispersing in an ultrasonic disperser. The components of the group (A) are uniformly mixed, and they are mixed with the components of the group (B) to form an emulsion by a homogenizer. Thereafter, the emulsion was mixed with the previously prepared (C) by hand stirring.

As a result, a cream containing anti-sac cells was produced.

Example 3. Sunscreen cosmetics

The reverse cystic solution (C) was prepared in the same manner as in Example 1 using (C-1 to 3) in advance. The ingredients of the group (A) were uniformly mixed by hand and heated to 80 °C. Further, the components of the group (B) were heated at 80 ° C to add a stirrer, and emulsified by a homogenizer. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (C) by hand stirring.

As a result, a sunscreen cosmetic containing anti-sac cells was produced.

Example 4. Emulsion type foundation cream

The reverse cystic solution (E) was prepared in the same manner as in Example 1 using (E-1 to 3) in advance. The ingredients of the group (A) were uniformly mixed by hand and heated to 80 °C. The components of the group (B) are dispersed in a mixture of the components of the group (A) by a disperser, and then the components of the component (C) are dispersed as a disperser. Using a homogenizer, the obtained oil phase was mixed with a (D) group uniformly mixed at 80 ° C and emulsified. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (E) by hand stirring.

As a result, an emulsion type foundation cream containing anti-sac cells was produced.

Example 5. Powder foundation cream

(A) anthrone treatment pigment pigment (titanium oxide, iron oxide) 15

The reverse cystic solution (B) was prepared in the same manner as in Example 1 using (B-1 to 5) in advance. After mixing the components of the group (A) and coarsely pulverizing them with a pulverizer, (B) was added and mixed by a Henschel mixer. After that, it was pulverized by a pulverizer and shaped on a metal disk.

As a result, a powder foundation cream containing anti-sac cells was produced.

<Anti-cyst composition of an anthrone-containing surfactant>

In the composition shown in Table 4, the components were mixed, and a layered phase was dispersed in an oil agent by a tubular ultrasonic disperser (product name: VCX130 (manufactured by Sonics & Materials)).

Thereafter, the formation of the anti-cyst was confirmed using an optical microscope. The formation of the anti-sac cells is described as ○, and the formation of the anti-sac cells is not confirmed as ×.

As shown in Table 4, the formation of the anti-cysts was confirmed using A to E of the anthrone surfactant.

From this, it is understood that it is possible to obtain an anti-cyst composition by using an fluorenone surfactant.

Hereinafter, examples of the skin external preparation (cosmetic) of the present invention will be described. The blending amount is expressed in mass percent.

Example 6. Hair oil

After premixing the components of the group (A), the components of the group (B) were mixed and dispersed by an ultrasonic disperser.

As a result, a hair styling containing anti-sac cells was produced.

Example 7. Cream

The anti-cytoplasmic solution (C) was prepared in the same manner as in Example 6 using (C-1 to 5) in advance. The components of the group (A) were uniformly mixed, and they were mixed with the components of the group (B) to form an emulsion by a homogenizer. Thereafter, the emulsion was mixed with (C) prepared in advance by hand stirring.

As a result, a cream containing anti-sac cells was produced.

Example 8. Sunscreen cosmetics

The anti-cytoplasmic solution (C) was prepared in the same manner as in Example 6 using (C-1 to 3) in advance. (A) The ingredients of the group were uniformly mixed by hand and heated to 80 °C. Among them, the component of the group (B) was heated and stirred at 80 ° C, and emulsified by a homogenizer. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (C) by hand stirring.

As a result, a sunscreen cosmetic containing anti-sac cells was produced.

Example 9. Emulsifying Foundation Cream

The anti-cytoplasmic solution (E) was prepared in the same manner as in Example 6 using (E-1 to 6) in advance. (A) The ingredients of the group were uniformly mixed by hand and heated to 80 °C. In the mixture of the components of the group (A), the components of the group (B) are dispersed by a disperser, and then the components of the component (C) are dispersed by a disperser. The obtained oil phase was mixed with the (D) group uniformly mixed at 80 ° C using a homogenizer, and emulsified. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with (E) prepared in advance by hand stirring.

As a result, an emulsion type foundation cream containing anti-sac cells was produced.

Example 10. Powder foundation cream

The reverse cystic solution (B) was prepared in the same manner as in Example 6 using (B-1 to 3) in advance. After mixing the components of the group (A) and coarsely pulverizing them with a pulverizer, (B) was added and mixed by a Henschel mixer. After that, it was pulverized by a pulverizer and shaped on a metal disk.

As a result, a powder foundation cream containing anti-sac cells was produced.

<Method for Producing Anti-cyst Composition 1>

The composition shown in Table 5 was used to produce an anti-cyst composition in the following manner.

That is, in the samples A to D, a mixture of the two-molecular film component and water (layered mixture) was dissolved in a volatile solvent to prepare an intermediate solution (first isotropic solution). Next, this intermediate solution was mixed with an oil to obtain a mixed solution. This solution is formed into two phases. Next, the mixed solution was stirred in a test tube shaker (Vortex Mixer) for 1 minute to obtain a dispersion (second isotropic solution) in which the intermediate solution was dispersed in the oil agent, and then heated to 35 ° C in a reduced pressure oven, and dried. To no volatile solvent.

Further, in the sample E, a mixture of the two-molecular film component and water was mixed with an oil agent, and the mixed solution was stirred in a test tube shaker under the same conditions as above.

The composition obtained was confirmed by a polarizing microscope using a polarizing microscope. The formation of the anti-sac cells is described as ○, and the formation of the anti-sac cells is not confirmed as ×.

As shown in Table 5, after the layered mixture was dissolved in a volatile solvent to prepare an intermediate solution, the formation of the anti-sac cells was confirmed by using samples A to D in which the mixture was mixed with an oil agent.

On the other hand, as in the case of the sample E of the method of directly mixing the layered mixture with the oil agent, the formation of the anti-cell was not confirmed.

From this, it is understood that the anti-cyst composition can be easily prepared by using a method in which the dimeric film component is previously dissolved in a volatile solvent, mixed with an oil agent, and then the volatile solvent is volatilized.

Further, in the case of the sample E, it was confirmed by the inventors that the anti-cell composition can be produced by imparting a stronger stirring force by using an ultrasonic disperser or the like. The production method of the present invention does not require a strong stirring force such as an ultrasonic disperser to produce a reverse cytoskeletal composition, and in this case, it can be said to be useful in industrial production or the like.

Further, in the case of using an oil agent having a larger molecular weight than the oil agent used in the present embodiment, the production method of the present invention is considered to be extremely useful.

Hereinafter, a production example of a skin external preparation (cosmetic) will be described. The amount of blending is expressed in mass percent.

Example 11. Hair oil

After dissolving the mixture of lecithin and water of the group (A) in a volatile solvent, the mixture was mixed with the components of the group (B), and the mixed solution was stirred for 1 minute in a test tube shaker. Next, the volatile solvent is removed by a conventional method.

As a result, a hair follicle (anti-cytoplasmic solution) containing anti-sac cells was produced.

Example 12. Cream

The reverse cystic solution (C) was prepared in the same manner as in Example 11 using (C-1, 2, 3). The components of the group (A) were uniformly mixed, mixed with the components of the group (B), and an emulsion was formed by a homogenizer. Thereafter, the emulsion was mixed with (C) prepared in advance by hand stirring.

As a result, a cream containing anti-sac cells was produced.

Example 13. Sunscreen Cosmetics

The anti-cytoplasmic solution (C) was prepared in the same manner as in Example 11 using (C-1 to 4) in advance. (A) The ingredients of the group are uniformly mixed by hand stirring , heated to 80 ° C. The ingredients of the group (B) were heated and stirred at 80 ° C, and emulsified by a homogenizer. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (C) by hand stirring.

As a result, a sunscreen cosmetic containing anti-sac cells was produced.

Example 14. Emulsifying Foundation Cream

The anti-cytoplasmic solution (E) was prepared in the same manner as in Example 11 using (E-1 to 4) in advance. The ingredients of the group (A) were uniformly mixed by hand and heated to 80 °C. After dispersing the components of the group (B) in a mixture of the components of the group (A), the components of the component (C) are dispersed as a disperser. Using a homogenizer, the obtained oil phase is uniformly mixed with 80 ° C (D) group plus To mix and emulsify. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (E) by hand stirring.

As a result, an emulsion type foundation cream containing anti-sac cells was produced.

Example 15. Powder Foundation Cream

The reverse cystic solution (B) was prepared in the same manner as in Example 1 using (B-1 to 6) in advance. After mixing the components of the group (A) and coarsely pulverizing them with a pulverizer, (B) was added and mixed by a Henschel mixer. After that, it is pulverized by a pulverizer and shaped into a metal disk.

As a result, a powder foundation cream containing anti-sac cells was produced.

<Method for Producing Anti-cyst Composition 2>

(1) Manufacture of anti-cyst composition

The composition shown in Table 6 was used, and the anti-cyst composition was produced in the following manner.

Namely, in the samples A to D, the two-molecular film component, water, and squalane were mixed at a ratio shown in Table 4, and heated to the heating temperature shown in Table 4. Either of the obtained solutions was an isotropic solution, which was confirmed by a polarizing plate. The phase number discrimination is a method in which a long-term sample is allowed to stand while maintaining a constant temperature to obtain an equilibrium state, or whether the appearance of the sample is observed to have turbidity. Next, the heated solution was allowed to stand to cool to the cooling chamber of the cooling temperature shown in Table 4. Each sample was cooled to a temperature that was transferred from the isotropic solution to the lamellar phase.

In Sample E, the concentration of the mixture of lecithin and water was adjusted to an isotropic solution of twice the concentration in Samples A to D, and finally squalane of 0 ° C was mixed at a ratio as shown in Table 4.

Further, in the sample F, a mixture of the two-molecular film component and water was mixed with an oil agent, and the mixed solution was stirred with a test tube shaker.

The composition of the obtained composition was confirmed using a polarizing microscope. The formation of the anti-sac cells is described as ○, and the formation of the anti-sac cells is not confirmed as ×.

As shown in Table 6, the samples A to E in which the mixture of the two-molecular film component and the oil agent were heated to prepare an isotropic solution and then cooled, the formation of the anti-sac cells was confirmed.

Further, it is understood that the method of cooling may be either a method of placing in a cooling chamber or a method of mixing a cooling oil agent.

On the other hand, as in the conventional manner, the sample F of the method of directly mixing the layered mixture with the oil agent was used, and the formation of the anti-cell was not confirmed.

From this, it is understood that the anti-cyst composition can be easily prepared by heating the mixture of the two-molecular film component and the oil agent to prepare an isotropic solution and then cooling the mixture.

Further, even in the case of the sample F, a stronger agitation force is imparted by using an ultrasonic disperser or the like, and a reverse cytoskeletal composition can be produced. The production method of the present invention does not require a strong stirring force such as an ultrasonic disperser to produce a reverse cytoskeletal composition. In this regard, it is considered to be useful in industrial production or the like.

Further, in the case of using an oil agent having a larger molecular weight than the oil agent used in the present embodiment, the production method of the present invention is considered to be extremely useful.

(2) particle size of the anti-sac

The average particle diameter (median diameter) of the samples A and B produced as described above was measured by a Malvern Zetasizer Nano ZS.

As a result, the average particle diameter shortly after the preparation of Sample A was about 500 nm, and the average particle diameter shortly after the preparation of Sample B was about 1000 nm.

From this, it can be seen that a minute anti-cyst can be produced by rapidly cooling the isotropic solution. At the same time, by changing the cooling rate, the anti-capsule can be controlled. The size of the cell.

Regarding these samples, it was found that when the particles were allowed to stand for one week or more, the sedimentation of the particles was started, but the dispersion was easily performed as necessary.

Hereinafter, a production example of a skin external preparation (cosmetic) will be described. The blending amount is expressed in mass percent.

Example 16. Hair oil

After mixing the components and heating to 90 ° C, the cooling chamber was equal to 0 ° C and cooled to about room temperature.

As a result, a hair follicle (anti-cytoplasmic solution) containing anti-sac cells was produced.

Example 17. Cream

The reverse cystic solution (C) was prepared in the same manner as in Example 16 using (C-1, 2). The components of the group (A) were uniformly mixed, and the components of the group (B) were mixed therein to form an emulsion by a homogenizer. Thereafter, the emulsion was mixed with (C) prepared in advance by hand stirring.

As a result, a cream containing anti-sac cells was produced.

Example 18. Sunscreen cosmetics

The anti-cytoplasmic solution (C) was prepared in the same manner as in Example 16 using (C-1 to 4) in advance. (A) The ingredients of the group were uniformly mixed by hand stirring and heated to 80 °C. The component of the group (B) was heated and stirred at 80 ° C, and emulsified by a homogenizer. Cool the emulsion to 35 ° C At this time, the emulsion was mixed with (C) prepared in advance by hand stirring.

As a result, a sunscreen cosmetic containing anti-sac cells was produced.

Example 19. Emulsifying Foundation Cream

The reverse cystic solution (E) was prepared in the same manner as in Example 16 using (E-1 to 4) in advance. (A) The ingredients of the group were uniformly mixed by hand stirring and heated to 80 °C. After dispersing the components of the group (B) in a mixture of the components of the group (A), the components of the component (C) are dispersed as a disperser. Using a homogenizer, the obtained oil phase was mixed with a (D) group uniformly mixed at 80 ° C and emulsified. The emulsion was cooled, and when it reached 35 ° C, the emulsion was mixed with the previously prepared (E) by hand stirring.

As a result, an emulsion type foundation cream containing anti-sac cells was produced.

Example 20. Powder Foundation Cream

The reverse cystic solution (B) was prepared in the same manner as in Example 16 using (B-1 to 5) in advance. After the components of the group (A) were mixed and coarsely pulverized by a pulverizer, (B) was added and mixed by a Henschel mixer. After that, it is pulverized by a pulverizer and shaped into a metal disk.

As a result, a powder foundation cream containing anti-sac cells was produced.

[Industrial availability]

The invention is applicable to the manufacture of cosmetics or foods.

1‧‧‧Dimolecular membrane composition

2‧‧‧ volatile solvent

3‧‧‧1st isotropic solution

4‧‧‧ oil agent

2.4‧‧‧One phase solution

5‧‧‧2nd isotropic solution

7‧‧‧Anti-cyst

8‧‧‧Anti-cyst composition

31‧‧‧ particles

Claims (34)

An anti-cyst composition comprising a lecithin-containing anti-sac cell and an oil agent having a molecular weight of greater than 114 g/mol and greater than 25 ° C. The anti-cyst composition of claim 1, wherein the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil. The anti-cyst composition of claim 1 or 2, wherein the aforementioned oil agent contains 40% by mass or more. The anti-cyst composition of any one of claims 1 to 3, wherein the aforementioned anti-cytoplasm contains water. The anti-cell composition of claim 4, wherein the water-containing mass is one time or less the mass of the constituent component of the bimolecular film containing lecithin. An anti-cyst composition comprising an anti-cytoplasm containing an anthrone surfactant and water, and a liquid agent at 25 ° C. The anti-cyst composition of claim 6, wherein the anthrone surfactant is selected from the group consisting of polyoxyethylene modified fluorenone, polyoxypropylene modified fluorenone, and polyoxyethylene. Polyoxypropylene modified fluorenone, and polyglycerol modified fluorenone. The anti-cyst composition of claim 6 or 7, wherein the aforementioned fluorenone surfactant has an HLB of from 3 to 13. The anti-cyst composition of any one of claims 6 to 8, wherein the oil agent is selected from the group consisting of an oxime oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluoro oil. The anti-cyst composition of any one of claims 6 to 9, which contains 40% by mass or more of the aforementioned oil agent. The anti-cyst composition according to any one of claims 6 to 10, wherein the water-containing mass is one time or less the mass of the two-molecular film constituent component of the fluorenone-containing surfactant. The anti-cyst composition of any one of claims 4 to 11, wherein the anti-cytoplasmic cell contains a water-soluble active ingredient. The anti-cyst composition of any one of claims 1 to 12 which is non-emulsifying. A skin external preparation containing the anti-cyst composition of any one of claims 1 to 13. A method for producing an anti-cyst composition comprising mixing lecithin and an oil component having a molecular weight of more than 114 g/mol and being liquid at 25 ° C to prepare a mixture, and then shaking or stirring the mixture. A method for producing an anti-cyst composition comprising mixing an anthrone surfactant, water, and a liquid component at 25 ° C to prepare a mixture, and then shaking or stirring the mixture. A method for producing an anti-cyst, which comprises recovering a reverse vesicle from the anti-cyst composition of any one of claims 1 to 13. A skin external preparation comprising a reverse vesicle manufactured by the method for producing an anti-sac cell of claim 17. A method for producing an anti-cyst composition, comprising the steps of: dissolving a dimeric film component in a volatile solvent to obtain a first isotropic solution; and mixing the first isotropic solution with an oil agent to obtain a step of second isotropic solution; a step of volatilizing the volatile solvent in the second isotropic solution; and a step of forming a reverse cyst of the dimeric membrane component by volatilization of a volatile solvent. The method for producing a reverse cyst composition according to claim 19, wherein the volatile solvent is selected from the group consisting of alcohols, hydrocarbons, aromatics, ketones, ethers, esters, volatile fluorenone oils, isoalkanes ( Isoparaffin). The method for producing an anti-cyst composition according to claim 19 or 20, wherein the first isotropic solution contains water having a mass of one or less times the mass of the two-molecular film component. The method for producing an anti-cyst composition according to any one of claims 19 to 21, wherein the second isotropic solution is a two-phase solution in which the particles of the first isotropic solution are dispersed in the oil agent. The method for producing an anti-cyst composition according to any one of claims 19 to 22, wherein the volatilization of the volatile solvent is carried out under reduced pressure. The method for producing an anti-cyst composition according to any one of claims 19 to 23, which comprises producing a reverse cyst containing lecithin and an oil having a molecular weight of more than 114 g/mol and being liquid at 25 ° C. A method of anti-cyst composition. A method for producing an anti-cyst composition comprising the steps of mixing and heating a two-molecular film component and an oil agent to obtain an isotropic solution; and cooling the isotropic solution; and by the aforementioned cooling, The step of forming a bi-molecular membrane component into the anti-sac cell. The method for producing an anti-cyst composition according to claim 25, wherein the isotropic solution contains water having a mass of one or less times the mass of the two-molecular film component. The method for producing a reverse cyst of claim 25 or 26, wherein the heating system is performed until the two molecules of the membrane component and the oil agent form a phase The temperature of the solution. The method for producing a reverse capsular cell according to claim 27, wherein the oil agent contains two or more oil agents, and the heating system is performed until the two molecules of the two molecular film components and the oil agent form one phase. The temperature of the isotropic solution. The method for producing an anti-cyst composition according to any one of claims 25 to 28, wherein the cooling system is performed by diluting the isotropic solution with a cooling solvent lower than the isotropic solution. The method of producing the anti-cyst composition of claim 29, wherein the cooling solvent comprises the aforementioned oil agent. The method for producing an anti-cyst composition according to any one of claims 25 to 30, which comprises producing a reverse cyst containing lecithin and an oil having a molecular weight of more than 114 g/mol and being liquid at 25 ° C. A method of anti-cyst composition. The method for producing an anti-cyst composition according to any one of claims 19 to 31, wherein the oil agent is selected from the group consisting of an anthrone oil, a hydrocarbon oil, an ester oil, a natural animal and vegetable oil, and a fluorine oil. The method for producing an anti-cyst composition according to any one of claims 19 to 32, wherein the dimolecular film component contains lecithin and/or a nonionic surfactant. A method for producing a skin external preparation, which comprises the step of mixing a reverse cytoskeleton composition produced by the method for producing a cytosolic composition according to any one of claims 19 to 33 with other components.